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Original scientific article

Aim: With the aim of improving personalized treatment of patients on chemotherapy, the objective of the study was to
assess the degree of association between selected Quality of life (QoL) indicators and both clinical and imaging cardiac
status indicators when detecting deterioration in QoL of these patients.
Methods: In a cohort clinical study in Hamburg, from August 2017 through October 2020, 59 cancer patients, aged 18-80
years, were evaluated before chemotherapy, and at several follow-ups, using EQ-5D and SF-36 QoL questionnaires, fast
strain-encoded (fast-SENC) cardiac magnetic resonance (CMR), conventional CMR, and echocardiography, and further
received a clinical and biomarker examination. Data was analyzed using survival analyses. A decline of more than 5% in
each observed QoL metric value was defined as the observed event. Patient were separated into groups according to
the presentation of cardiotoxicity as per its clinical definition, the establishment of the indication for cardioprotective
therapy initiation, and by a worsening in the value of each observed imaging metric by more than 5% in the previous
follow-up compared to the corresponding pre-chemotherapy baseline value.
Results: Among clinical cardiac status indicators, the indication for cardioprotective therapy showed statistically good
association with QoL scores (EQ-5D p=0.028; SF-36 physical component p=0.016; SF-36 mental component p=0.012). In
terms of imaging metrics, the MyoHealth segmental myocardial strain score was the only one demonstrating consistently
good QoL score association (EQ-5D p=0.005; SF-36 physical component p=0.056; SF-36 mental component p=0.002).
Conclusions: Established fast-SENC CMR scores are capable of highlighting patients with reduced QoL, who require
more frequent/optimal management.
Namen: Z namenom izboljšati personalizirano zdravljenje bolnikov, ki prejemajo kemoterapijo, je bil cilj naše raziskave
oceniti stopnjo povezanosti med izbranimi kazalniki kakovosti življenja (QoL) ter kliničnimi in slikovnimi kazalniki
srčnega statusa v kontekstu zaznave poslabšanja QoL teh bolnikov.
Metode: V kohortni klinični študiji v Hamburgu smo od avgusta 2017 do oktobra 2020 59 bolnikom z rakom, starim
18–80 let, pred kemoterapijo in več kontrolnimi pregledi, napravili oceno QoL z vprašalnikoma EQ-5D in SF-36, hitro z
deformacijo miokarda kodirano (fast-SENC) magnetnoresonančno slikanje srca (CMR), konvencionalno CMR, ultrazvočni
pregled srca ter klinični pregled z določitvijo biomarkerjev. Podatke smo analizirali z analizo preživetja. Upad za več
kot 5 % v vrednosti posameznega opazovanega kazalnika QoL je bil izbran kot opazovani dogodek. Razdelitev bolnikov v
skupine je bila definirana glede na pojav kardiotoksičnosti po njeni klinični definiciji, postavitev indikacije za zdravljenje
z zdravili za zaščito srčne mišice ter na osnovi poslabšanja vrednosti posameznega opazovanega slikovnega kazalnika za
več kot 5 % ob zadnjem kontrolnem pregledu v primerjavi z njegovo vrednostjo pred pričetkom kemoterapije.
Rezultati: Med kliničnimi kazalniki srčnega statusa je postavitev indikacije za zdravljenje z zdravili za zaščito srčne
mišice pokazala statistično dobro povezanost s kazalniki QoL (EQ-5Dp = 0,028; SF-36 telesna komponenta p = 0,016; SF36 mentalna komponenta p = 0,012). Med slikovnimi kazalniki je bila MyoHealth ocena segmentne krčljivosti miokarda
edina, ki je pokazala konsistentno dobro povezanost s kazalniki QoL (EQ-5D p = 0,005; SF-36 telesna komponenta p =
0,056; SF-36 mentalna komponenta p = 0,002).
Zaključek: Uveljavljeni fast-SENC kazalniki CMR so se pokazali za sposobne izpostaviti bolnike z zmanjšano QoL, ki
potrebujejo pogostejšo/optimalnejšo obravnavo.

*Corresponding author: E-mail: blaz.gersak@maat.si
© National Institute of Public Health, Slovenia.
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1 INTRODUCTION
In the past 20 years, systemic cancer therapy has
advanced considerably, lowering mortality and increasing
life expectancy. With a substantially increased proportion
of cancer survivors treated with chemotherapy, long
term consequences of systemic chemotherapeutics
have become a very important factor in the context
of public health. A very prominent one among those is
cardiovascular dysfunction due to cardiotoxic effects of
chemotherapeutic regimes (1). Moreover, it is important
to recognize that cancer patient quality of life (QoL)
is also influenced by cardiovascular health (2), whose
management is an important part of personalized patient
management, which has been shown to improve survival
and QoL in cancer patients (3), and has expanded to form
its own clinical sub-field of cardio-oncology.
Chemotherapy drugs such as anthracyclines, taxanes,
targeted biological therapies (trastuzumab, etc.), and
drug combinations, with or without concomitant radiation
therapy, have been shown to cause cardiotoxicity leading
to heart failure (4, 5). In patients receiving anthracycline
therapy, the incidence of chemotherapy-induced
cardiotoxicity is approximately 30%, and can surpass many
malignancies as the leading cause of mortality (6).
In the context of patient QoL, the clinical status as observed
by the clinician is not reliable. It has been shown that
attending physicians often underestimate chemotherapyrelated symptom severity and frequency, with low
sensitivity and specificity for detecting side effects of
chemotherapy with or without concomitant radiation
therapy, resulting in less than optimal treatment course
decisions regarding chemotherapy continuation, halting, or
dose alteration, as well as worse patient QoL (7).
It has also been shown that regular patient self-evaluation
and reporting of QoL status can significantly improve
physical and mental QoL metrics, reduce emergency room
admittance, and even extend mean survival in patients
with solid tumors by as much as 5 months, without
increasing the cost in health resources (8).
Cardiac magnetic resonance (CMR) strain testing (strainencoded, harmonic phase analysis) has been shown to
detect cardiotoxicity before systemic changes occur. CMR
strain has been shown to detect abnormal myocardial
function in cancer patients treated with high-dose
anthracycline chemotherapy despite normal systolic
function by traditional metrics, namely traditional CMR
and echocardiographic (ECHO) left ventricular ejection
fraction (LVEF) (9).
With the aim of improving personalized treatment of patients
on chemotherapy, the study’s objective was to assess the
degree of association between selected QoL indicators and
both clinical and imaging cardiac status indicators when
detecting deterioration in these patients’ QoL.
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2 METHODS
2.1 Study design
This study was part of the PREFECT research project
(ClinicalTrials.gov identifier NCT03543228) (10), and was
designed as a prospective cohort clinical study, performed
in its entirety at the Katholisches Marienkrankenhaus
GmbH.
2.2 Study population
In the period between August 2017 and July 2019, 63 patients
were screened for their consent to study participation.
The inclusion criteria were: age 18 to 80 years, any
gender, in the case of women the absence of pregnancy,
no contraindications for magnetic resonance imaging,
breast cancer, non-Hodgkin’s or Hodgkin’s lymphoma, no
history of prior chemotherapy or renal failure, a glomerular
filtration rate of higher than 30ml/kg/m2, and an indication
to undergo chemotherapy for cancer treatment with or
without concomitant radiation therapy. Those who agreed
to participate, having provided written informed consent,
were subsequently enrolled in the study.
2.3 Data collection procedure
Anti-cancer medications were prescribed at the attending
oncologist’s discretion, as per current European Society
for Medical Oncology clinical practice guidelines (11).
Patients with breast cancer were treated with epirubicin
and cyclophosphamide every 3 weeks for a total of 4
cycles, followed by 12 weekly cycles of paclitaxel (EC-P);
a few patients received dose-dense EC-P. Patients with
HER2+ breast cancer were treated with trastuzumab and
radiation therapy. Patients with non-Hodgkin’s lymphoma
were treated with cyclophosphamide, doxorubicin,
vincristine, and prednisone with rituximab (R-CHOP),
while patients with Hodgkin’s lymphoma were treated
with a combination therapy including anthracyclines with
or without radiation therapy.
Subjects were evaluated at baseline, 3-months, 6-months
and 1-year follow-ups, and additionally as needed in
between designated follow-up time points, using fast
strain-encoded (fast-SENC) CMR, conventional CMR, and
ECHO. They also had blood drawn for routine biochemical
testing, including cardiac biomarker evaluation (troponin,
brain natriuretic peptide, N-terminal pro b-type natriuretic
peptide). At same time points as the above mentioned
tests, all subjects were evaluated at the study location,
with appropriate guidance, using EQ-5D and SF-36 QoL
questionnaires.
2.4 Data collection instruments
2.4.1 QoL status measurement instruments
EQ-5D is a questionnaire-based tool for patient self-reported
generic QoL measurement, developed and maintained by
200
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the EuroQol Research Foundation. It combines a measure
with five preference-based questions, and a visual analog
scale (VAS). The five questions each describe one generic
QoL aspect: mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression, with two possible
responses (absence of problems, presence of problems) in
each. The responses were converted into index and utility
scores anchored at 0 for death and 1 for perfect health.
The VAS provides a measure of perceived health status
with a grade ranging from 0 (the worst possible health
status) to 100 (the best possible health status) (12, 13). For
the purpose of our study, we observed changes in the VAS
score. The questionnaire has been in regular use in the
clinical setting in the Germanophone world since 1998,
after its German translation was validated (14). A newer
version of the questionnaire, the EQ-5D-5L, providing 5
possible responses ranging from the worst possible health
status to the best possible health status, was thereupon
validated on the German population in 2014 (15). In our
study, we used the original 2-level version, whose VAS
component is the same as in the 5-level version.
SF-36 is a 36-item questionnaire-based tool for patient selfreported health-related QoL measurement, developed and
maintained by the RAND Corporation. It has eight basic
scores, describing different aspects of health-related QoL:
physical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional, and
mental health. Each score is calculated (with weighting)
from several preference-based questions with possible
responses ranging from the worst possible health status
to the best possible health status in either 2, 3, 5, or 6
increments, depending on the question. From the noted
basic scores, two combined scores are derived: a physical
health component score and a mental health component
score. SF-36 also includes a single combined overview
score, also derived from the eight basic scores, describing
perceived change in patient’s health status over the past
year. Calculating each of the noted basic and combined
scores gives a score ranging from 0 to 100. Higher scores
indicate a better health status, and a mean score of 50 has
been articulated as a normative value for all scores (16,
17). For the purpose of our study, we observed changes
in the physical and mental component scores. The
questionnaire has been in regular use in the clinical setting
in the Germanophone world since 1994, since its German
translation was validated (18). It was validated again in
1999 on a larger population of 6964 survey participants,
resulting in a description of an updated German normative
population sample (18).
2.4.2 Cardiac status measurement instruments
All traditional CMR and fast-SENC CMR measurements
were performed with electrocardiogram triggering on the
R-wave on a 1.5 Tesla Achieva magnetic resonance imaging
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scanner, Philips Medical Systems International BV. Each
patient received a comprehensive baseline CMR exam
before initiating chemotherapy, which included steadystate free precession with global calculations (LVEF,
volumes, mass), strain-encoded CMR, fast-SENC CMR, T1
and T2-weighted mapping, and adenosine perfusion stress
testing. Conventional CMR acquisitions, including T1 and
T2-weighted mapping images and strain-encoded CMR,
were analyzed using the CVI 42 software package, Circle
Cardiovascular Imaging, as per the manufacturer’s training
and recommendations. Fast-SENC CMR circumferential
and longitudinal left ventricle and right ventricle strain
were calculated and analyzed using the MyoStrain 5.0
software package Myocardial Solutions, Inc., as per the
manufacturer’s training and recommendations, to provide
a validated, standardized left ventricle and right ventricle
end-systolic segmental and global longitudinal and
circumferential strain metrics (19).
ECHO LVEF was measured by the Simpson’s method
from biplane planes from the 2-chamber and 4-chamber
views according to the manufacturer’s training and
recommendations. ECHO global longitudinal strain
(GLS) was measured using speckle tracking algorithms
incorporated into the Affiniti 50 G ultrasound machine,
Philips Medical Systems International BV, according to
manufacturer training and recommendations.
All laboratory analyses were performed as per standard
operating procedures at the study institution’s laboratories
as well as an outsourced laboratory, HämatologischOnkologische Praxis Altona.
2.5 Data analysis
2.5.1 QoL status indicators
An event was deemed to have occurred if a drop of more
than 5% in each respective QoL status indicator score (EQ5D score, SF-36 physical component score, SF-36 mental
component score) was recorded as compared to its
associated pre-chemotherapy value. The timepoint at the
described event was thus recorded. If no event occurred,
the last timepoint and QoL value was recorded. The
observed outcome was the time (in days) from the baseline
pre-chemotherapy examination to the target event.
In the analysis, three outcomes were observed: time to a
drop of more than 5% in the EQ-5D score, time to a drop
of more than 5% in the SF-36 physical component score,
and time to a drop of more than 5% in the SF-36 mental
component score.
2.5.2 Cardiac status indicators
The development of symptomatic heart failure, a
significant reduction in LVEF, or cardiac biomarker
indicators of myocardial injury were used to classify
patients with subclinical cardiotoxicity and clinical
201
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cardiotoxicity based on the American Society of
Echocardiography Expert Consensus Position Paper, the
European Society of Cardiology Position Paper, and the
European Society for Medical Oncology clinical practice
guidelines (11, 20, 21). Fast-SENC CMR was not used in
categorizing cardiotoxicity status. Clinical cardiotoxicity
was defined as an absolute change in LVEF from greater
than 10% from baseline to below 53%, combined with
heart failure symptoms or abnormal cardiac biomarker
values (troponin, brain natriuretic peptide, or N-terminal
pro b-type natriuretic peptide). Subclinical cardiotoxicity
was defined as an asymptomatic patient with a greater
than 15% decrease in LVEF that remains greater or equal
to 53%, worsening in GLS of more than 15% from baseline,
or abnormal cardiac biomarker values (troponin, brain
natriuretic peptide, or N-terminal pro b-type natriuretic
peptide). Patients with clinical cardiotoxicity and those
with subclinical cardiotoxicity were combined into the
“Cardiotoxicity” group, while the rest fell into the “No
Cardiotoxicity” group.
The indication to initiate cardioprotective therapy was
made at the discretion of the treating oncologist in
consultation with a cardiologist. Establishment of the
indication to initiate cardioprotective therapy was used to
separate patients into the “Cardioprotection Indicated”
and “No Cardioprotection Indicated” groups. Every patient
who was indicated to receive cardioprotective therapy did
do so.
Whether or not the value of each respective cardiac
imaging indicator (traditional CMR LVEF, traditional CMR
GLS, ECHO LVEF, ECHO GLS, fast-SENC CMR LVEF, fastSENC CMR standard parameters) worsened by more than
5% in the last follow-up compared to the corresponding
pre-chemotherapy baseline value, was used to separate
patients into the “Did Not Maintain Baseline” and
“Maintained Baseline” groups for each respective cardiac
imaging indicator. If a specific cardiac imaging indicator
value worsened by more than 5%, the patient was grouped
under “Did Not Maintain Baseline” for that specific cardiac
imaging indicator Otherwise, it was grouped under
“Maintained Baseline” for that specific cardiac imaging
indicator. An indicator’s worsening was indicated by a
value decrease in LVEF measurements and fast-SENC
CMR standard parameters, and a value increase in raw
myocardial strain measurements (GLS).
2.5.3 Statistical analysis
Kaplan-Meier product limit statistic, along with the logrank test, was used to assess the relationship between the
observed QoL indicators and cardiac status indicators. The
curves and statistics were graphed and calculated using
Python 3.x, Python Software Foundation, with the lifelines
0.25.x package, https://github.com/CamDavidsonPilon/
lifelines. P-values of <0.05 were considered statistically
significant.
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3 RESULTS
3.1 Observed patient group
All 63 patients who met the inclusion criteria agreed to
participate and were enrolled into the study.
Of the 63 enrolled patients, 3 were excluded due to a
change in therapy plan (non-chemotherapy cancer
treatment), while another 1 patient was lost to followups beyond the first visit. Results using the outcomes for
the remaining 59 patients were subsequently used in all
analyses.
Our population included 50 female and 9 male patients,
with a median age of 51 years and mean of 53.9±14.5
years, respectively. Baseline QoL score values in the
population were: EQ-5D median 75, mean 69.4±24.0; SF36 physical component median 54.4, mean 51.1±8.6; SF-36
mental component median 44.8, mean 45.5±9.6.
3.2 Survival analyses
3.2.1 EQ-5D
Results of the association analysis for the observed EQ-5D
outcomes are shown in Figures 1-3.

A

B

Figure 1. EQ-5D questionnaire events – (A) clinical definition
of cardiotoxicity; (B) clinical indication for
cardioprotective therapy initiation; Germany,
single-center study, August 2017 through October
2020, chemotherapy for cancer treatment.

Clinical cardiotoxicity definition (Figure 1A) and the
indication for cardioprotective therapy initiation (Figure
1B) both show statistically good association with EQ-5D
scores.
Figure 2 shows that a worsening of more than 5% in
the last follow-up compared to the corresponding prechemotherapy baseline value in LVEF measurement values
shows no association with EQ-5D scores, irrespective of
the method used to obtain those values.
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B

C

Figure 2. EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left
ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C)
MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center
study, August 2017 through October 2020, chemotherapy for cancer treatment.

A

B

C

D

E

F

Figure 3. EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global
longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH,
(D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and
circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain,
respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
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A worsening of more than 5% in the last follow-up
compared to the corresponding pre-chemotherapy
baseline value in segmental myocardial strain scores all
show either statistically good association (Figure 3C, D
and E) or borderline association (Figure 3F) with EQ-5D
scores, while there is no association between a worsening
of more than 5% in the last follow-up compared to the
corresponding pre-chemotherapy baseline value in any
of the observed global myocardial strain measurement
values and EQ-5D scores, irrespective of the method used
to obtain those values.
3.2.2 SF-36 physical component
Results of the association analysis for the observed SF-36
physical component outcomes are shown in Figures 4-6.
The clinical cardiotoxicity definition (Figure 4A) and the
indication for cardioprotective therapy initiation (Figure
4B) both show a statistically good association with SF-36
physical component scores.

A

B

A

B

Figure 4. SF-36 physical component questionnaire events –
(A) clinical definition of cardiotoxicity; (B) clinical
indication for cardioprotective therapy initiation;
Germany, single-center study, August 2017 through
October 2020, chemotherapy for cancer treatment.

C

Figure 5. SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF –
echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular
ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction;
Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

Figure 5 shows that a worsening of more than 5% in
the last follow-up compared to the corresponding prechemotherapy baseline value in LVEF measurement values
shows no association with SF-36 physical component
scores, irrespective of the method used to obtain those
values.

A worsening of more than 5% in the last follow-up compared
to the corresponding pre-chemotherapy baseline value
in the MyoHealth score (Figure 6C) shows borderline
association with SF-36 physical component scores, while a
worsening of more than 5% in the last follow-up compared
to the corresponding pre-chemotherapy baseline value in
all other observed myocardial strain indicators show no
association with SF-36 physical component scores.
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A

B

C

D

E

F

Figure 6. SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS –
echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal
strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle
longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11%
or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer
treatment.

3.2.3 SF-36 mental component
Results of the association analysis for the observed SF-36
mental component outcomes are shown in Figures 7-9.

A

B

The indication for cardioprotective therapy initiation
(Figure 7B) shows a statistically good association with SF-36
mental component scores, while the clinical cardiotoxicity
definition (Figure 7A) shows borderline association with
SF-36 mental component scores.
Figure 8 shows that a worsening of more than 5% in
the last follow-up compared to the corresponding prechemotherapy baseline value in LVEF measurement values
shows no association with SF-36 mental component scores,
irrespective of the method used to obtain those values.

Figure 7. SF-36 mental component questionnaire events – (A)
clinical definition of cardiotoxicity; (B) clinical
indication for cardioprotective therapy initiation;
Germany, single-center study, August 2017 through
October 2020, chemotherapy for cancer treatment.
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B

C

Figure 8. SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF –
echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular
ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction;
Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.

A

B

C

D

E

F

Figure 9. SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS –
echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal
strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle
longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11%
or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer
treatment.
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A worsening of more than 5% in the last follow-up compared
to the corresponding pre-chemotherapy baseline value
in the MyoHealth score (Figure 9C) shows a statistically
good association with SF-36 mental component scores, a
worsening of more than 5% in the last follow-up compared
to the corresponding pre-chemotherapy baseline value
in the percent of MyoStrain segments with contraction
values of ≤-11% (Figure 9E) shows a borderline association
with SF-36 mental component scores, while a worsening
of more than 5% in the last follow-up compared to the
corresponding pre-chemotherapy baseline value in all
other observed myocardial strain indicators show no
association with SF-36 mental component scores.

4 DISCUSSION
The differentiation in EQ-5D, SF-36 physical component
and SF-36 mental component, observed in MyoHealth
and Functional MyoStrain, successfully highlights the
injury occurring from chemotherapy, which manifests in
reduced QoL. Moreover, across each of the QoL metrics,
MyoHealth was the single imaging parameter that
consistently demonstrated the best delineation. Since
MyoHealth correctly identified several events, the validity
of associated statistical analyses, which showed that QoL
results are best delineated by injury based on MyoStrain,
is reinforced, suggesting that early identification of
subclinical cardiotoxicity using fast-SENC CMR, with
associated cardioprotection, may be able to impact QoL.
Studies investigating QoL in cancer patients, more so
cardiac patients in general, are numerous, both in the
local (8, 22-24) and worldwide setting, as are those that
investigate ECHO and traditional CMR measurements in
relation to patient QoL. Comparison with similar studies
to ours however is practically impossible due to the fact
that fast-SENC CMR, as confirmed by the manufacturer,
has never been analyzed in respect to patient QoL in
any clinical scenario, including oncology. The only study
done with fast-SENC CMR in vague relation to QoL was
an economic evaluation of fast-SENC CMR in the diagnosis
and management of early heart failure by Schneider and
Stojanovic, published in 2019 (25).
Our study is limited by a few factors. The most important
one is that the findings could be confounded by the impact
of chemotherapy, cardioprotective medications, radiation
therapy, comorbidities, age, and human psychology on
perceived QoL. Chemotherapy and cardioprotective
medications are known to have side effects that patients
can perceive as reducing physical or mental conditions and
therefore can impact EQ-5D, SF-36 physical component,
and SF-36 mental component calculations. Radiation
therapy is known to have a negative effect on regional
myocardial performance, which is especially important
in patients with breast cancer (26). Patients with a more

Zdr Varst. 2021;60(4):199-209

extensive array of comorbidities are much more likely to
receive cardioprotection, which is bound to positively
affect their QoL status both through the actual as well
as placebo effects of cardioprotective medication, as
opposed to their not cardioprotected counterparts.
Lastly, age is also an important confounder in patient
QoL self-estimation. To get around the noted limitations,
multivariate models would need to be developed. Due
to the small sample size however, this was not possible.
The next limitation was the effect of differing patientperceived QoL starting points at the baseline on observed
data. The starting baseline QoL status after a confirmed
diagnosis of cancer was bound to be higher in younger
patients and those with fewer or no prior comorbidities,
compared to older ones and those with more significant
concomitant diseases. In our study, this was merited by
observing the relative drop in QoL status, and thus the
noted observation does not affect our conclusions. Finally,
the log-rank test may not have been the best test choice
in all cases, but we considered it good enough to roughly
estimate the statistical significance of the differences.
On the other hand, our study also has some important
strengths. The primary one is the fact that it is the first
to investigate fast-SENC CMR in respect to patient QoL in
any clinical scenario, both within and without the field of
cardio-oncology. Also, using the Kaplan-Meier product limit
statistic as the analysis tool, while not standard for this type
of study, gives our results an additional time component,
adding deeper insight into our observed population.
Our findings contribute in a meaningful way to both
the cardio-oncology and public health fields. Fast-SENC
CMR could, in addition to its original intended use for
early cardiotoxicity detection and prediction, give
regular follow-up imaging examinations an additional
screening and diagnostic quality, both if used alongside
questionnaire-based QoL analysis tools or without. In this
context, fast-SENC CMR would serve as an indicator of
the effect of anti-cancer therapy on the cardiovascular
component of a patient’s QoL, not influenced by other
unwanted side effects of cancer treatment and elements
from personal life that can influence various dedicated
QoL tool scores. This would give the clinician valuable
objective insight into this very important component of
the overall patient QoL, which, if managed early with
cardioprotective therapy, could greatly aid in quality
personalized management of cancer patients, resulting in
higher survival rates (3), better quality adjusted life years,
and a lower burden on the healthcare system.
Numerous questions remain unanswered within the
general topic our study. Firstly, a study on a larger
patient population is merited. Furthermore, based on
our findings, higher-risk patients could benefit from
cardioprotective therapy that is instigated preemptively,
even before subclinical changes in cardiac function can be
207
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detected. In light of this, it could be beneficial to expand
upon the scope of the research project this study is a part
of by performing a randomized controlled trial on a select
high-risk patient-group that could potentially benefit
from initiation of cardioprotective therapy at the very
beginning of their chemotherapy regimen. Moreover, for
determining the optimal type, combination and regimen
of cardioprotective therapy in cancer patients in general,
another randomized controlled trial using fast-SENC CMR
to follow patients’ cardiac status would also be extremely
beneficial, especially in the context of alleviating the
public health burden imposed by the cardiotoxicity of
chemotherapy and radiation therapy.

5 CONCLUSIONS
Established fast-SENC CMR scores including MyoHealth
and Functional MyoStrain delineated patients who
were predisposed to reduced QoL. The importance of
appropriately classifying patients at risk of developing
cardiotoxicity before and during cancer treatment has
valuable potential clinical implications of highlighting
patients who need to be monitored more frequently and
managed more optimally.
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